AbbVie Inc (ABBV)vsTeleflex Incorporated (TFX)
ABBV
AbbVie Inc
$290.89
+1.68%
HEALTHCARE · Cap: $504.37B
TFX
Teleflex Incorporated
$138.98
-0.01%
HEALTHCARE · Cap: $5.53B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2756% more annual revenue ($64.39B vs $2.25B). ABBV leads profitability with a 9.8% profit margin vs -45.8%. TFX appears more attractively valued with a PEG of 0.16. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
TFX
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$290.89
$137.92 premium
Margin of Safety
+9.1%
Fair Value
$117.70
Current Price
$138.98
$21.28 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 28.9% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Distress zone — elevated risk
ROE of -32.7% — below average capital efficiency
Earnings declined 17.3%
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : TFX
The strongest argument for TFX centers on PEG Ratio, Price/Book, Revenue Growth. Revenue growth of 28.9% demonstrates continued momentum. PEG of 0.16 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : TFX
The primary concerns for TFX are Altman Z-Score, Return on Equity, EPS Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while TFX is a growth play — different risk/reward profiles.
TFX carries more volatility with a beta of 0.83 — expect wider price swings.
TFX is growing revenue faster at 28.9% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 52/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Teleflex Incorporated
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?